Abstract
Background: The drugs available for the treatment of Chagas disease are ineffective in its chronic phase and produce many adverse effects, making the search for new drugs an urgent medical need.
Objective: This study aimed to design, synthesize, and evaluate the trypanocidal and cytotoxic profiles of new 4-nitroimidazole prototypes.
Methods: The new compounds were synthesized in overall yields ranging from 31-to 52% through the use of classical and reproducible methodologies. Their trypanocidal profile and cytotoxicity were assayed against trypomastigote forms of T. cruzi and mammalian macrophages, respectively.
Results: The best trypanocidal activity was evidenced in compounds that present lipophilic and electronegative substituents, e.g. 4-chlorophenyl derivative (5), with an IC50 = 206.98 μM;
Conclusion: The new benznidazole N-glycinyl-hydrazone analogues demonstrated a very significant reduction in the trypanocidal activity compared to benznidazole, which seems to be related to the position occupied by the nitro group in the imidazole ring.
Keywords: Trypanocidal activity, chagas disease, Trypanosoma cruzi, hydrazones, 4-nitroimidazoles, acylhydrazones.
Graphical Abstract
[1]
Chagas, C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem. Inst. Oswaldo Cruz, 1909, 1(2), 159-218.
[http://dx.doi.org/10.1590/S0074-02761909000200008]
[http://dx.doi.org/10.1590/S0074-02761909000200008]
[2]
WHO. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly. Epidemiol. Rec., 2015, 90(6), 33-43.
[PMID: 25671846]
[PMID: 25671846]
[3]
Rassi, A., Jr; Rassi, A.; Marin-Neto, J.A. Chagas disease. Lancet, 2010, 375(9723), 1388-1402.
[http://dx.doi.org/10.1016/S0140-6736(10)60061-X] [PMID: 20399979]
[http://dx.doi.org/10.1016/S0140-6736(10)60061-X] [PMID: 20399979]
[4]
Malik, L.H.; Singh, G.D.; Amsterdam, E.A. The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease. Clin. Cardiol., 2015, 38(9), 565-569.
[http://dx.doi.org/10.1002/clc.22421] [PMID: 25993972]
[http://dx.doi.org/10.1002/clc.22421] [PMID: 25993972]
[5]
Salvador, F.; Treviño, B.; Sulleiro, E.; Pou, D.; Sánchez-Montalvá, A.; Cabezos, J.; Soriano, A.; Serre, N.; Gómez, I.; Prat, J.; Pahissa, A.; Molina, I. Trypanosoma cruzi infection in a non-endemic country: epidemiological and clinical profile. Clin. Microbiol. Infect., 2014, 20(7), 706-712.
[http://dx.doi.org/10.1111/1469-0691.12443] [PMID: 24329884]
[http://dx.doi.org/10.1111/1469-0691.12443] [PMID: 24329884]
[6]
Rodriques Coura, J.; de Castro, S.L. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz, 2002, 97(1), 3-24.
[http://dx.doi.org/10.1590/S0074-02762002000100001] [PMID: 11992141]
[http://dx.doi.org/10.1590/S0074-02762002000100001] [PMID: 11992141]
[7]
Coura, J.R.; Borges-Pereira, J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem. Inst. Oswaldo Cruz, 2011, 106(6), 641-645.
[http://dx.doi.org/10.1590/S0074-02762011000600001] [PMID: 22012216]
[http://dx.doi.org/10.1590/S0074-02762011000600001] [PMID: 22012216]
[8]
Castro, J.A.; de Mecca, M.M.; Bartel, L.C. Toxic side effects of drugs used to treat Chagas’ disease (American trypanosomiasis). Hum. Exp. Toxicol., 2006, 25(8), 471-479.
[http://dx.doi.org/10.1191/0960327106het653oa] [PMID: 16937919]
[http://dx.doi.org/10.1191/0960327106het653oa] [PMID: 16937919]
[9]
Papadopoulou, M.V.; Bloomer, W.D.; Rosenzweig, H.S.; Wilkinson, S.R.; Kaiser, M. Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents. Eur. J. Med. Chem., 2014, 87, 79-88.
[http://dx.doi.org/10.1016/j.ejmech.2014.09.045] [PMID: 25240098]
[http://dx.doi.org/10.1016/j.ejmech.2014.09.045] [PMID: 25240098]
[10]
Papadopoulou, M.V.; Bloomer, W.D.; Rosenzweig, H.S.; O’Shea, I.P.; Wilkinson, S.R.; Kaiser, M. 3-Nitrotriazole-based piperazides as potent antitrypanosomal agents. Eur. J. Med. Chem., 2015, 103, 325-334.
[http://dx.doi.org/10.1016/j.ejmech.2015.08.042] [PMID: 26363868]
[http://dx.doi.org/10.1016/j.ejmech.2015.08.042] [PMID: 26363868]
[11]
Salerno, A.; Celentano, A.M.; López, J.; Lara, V.; Gaozza, C.; Balcazar, D.E.; Carrillo, C.; Frank, F.M.; Blanco, M.M. Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity. Eur. J. Med. Chem., 2017, 125, 327-334.
[http://dx.doi.org/10.1016/j.ejmech.2016.09.045] [PMID: 27688187]
[http://dx.doi.org/10.1016/j.ejmech.2016.09.045] [PMID: 27688187]
[12]
Bermudez, J.; Davies, C.; Simonazzi, A.; Real, J.P.; Palma, S. Current drug therapy and pharmaceutical challenges for Chagas disease. Acta Trop., 2016, 156, 1-16.
[http://dx.doi.org/10.1016/j.actatropica.2015.12.017] [PMID: 26747009]
[http://dx.doi.org/10.1016/j.actatropica.2015.12.017] [PMID: 26747009]
[13]
Duarte, C.D.; Barreiro, E.J.; Fraga, C.A.M. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev. Med. Chem., 2007, 7(11), 1108-1119.
[http://dx.doi.org/10.2174/138955707782331722] [PMID: 18045214]
[http://dx.doi.org/10.2174/138955707782331722] [PMID: 18045214]
[14]
Ifa, D.; Rodrigues, C.R.; de-Alencastro, R.B.; Fraga, C.A.M.; Barreiro, E.J. A possible molecular mechanism for the inhibition of cysteine proteases by salicylaldehyde N-acylhydrazones and related compounds. J. Mol. Struct. THEOCHEM, 2000, 505(1-3), 11-17.
[http://dx.doi.org/10.1016/S0166-1280(99)00307-3]
[http://dx.doi.org/10.1016/S0166-1280(99)00307-3]
[15]
Li, R.; Chen, X.; Gong, B.; Selzer, P.M.; Li, Z.; Davidson, E.; Kurzban, G.; Miller, R.E.; Nuzum, E.O.; McKerrow, J.H.; Fletterick, R.J.; Gillmor, S.A.; Craik, C.S.; Kuntz, I.D.; Cohen, F.E.; Kenyon, G.L. Structure-based design of parasitic protease inhibitors. Bioorg. Med. Chem., 1996, 4(9), 1421-1427.
[http://dx.doi.org/10.1016/0968-0896(96)00136-8] [PMID: 8894100]
[http://dx.doi.org/10.1016/0968-0896(96)00136-8] [PMID: 8894100]
[16]
Thota, S.; Rodrigues, D.A.; Pinheiro, P.S.M.; Lima, L.M.; Fraga, C.A.M.; Barreiro, E.J. N-Acylhydrazones as drugs. Bioorg. Med. Chem. Lett., 2018, 28(17), 2797-2806.
[http://dx.doi.org/10.1016/j.bmcl.2018.07.015] [PMID: 30006065]
[http://dx.doi.org/10.1016/j.bmcl.2018.07.015] [PMID: 30006065]
[17]
(a) Jose Cazzulo, J.; Stoka, V.; Turk, V. The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease. Curr. Pharm. Des., 2001, 7(12), 1143-1156.
[http://dx.doi.org/10.2174/1381612013397528] [PMID: 11472258];
(b) Doyle, P.S.; Zhou, Y.M.; Hsieh, I.; Greenbaum, D.C.; McKerrow, J.H.; Engel, J.C. The Trypanosoma cruzi protease cruzain mediates immune evasion. PLoS Pathog., 2011, 7(9), e1002139.
[http://dx.doi.org/10.1371/journal.ppat.1002139] [PMID: 21909255]
[http://dx.doi.org/10.2174/1381612013397528] [PMID: 11472258];
(b) Doyle, P.S.; Zhou, Y.M.; Hsieh, I.; Greenbaum, D.C.; McKerrow, J.H.; Engel, J.C. The Trypanosoma cruzi protease cruzain mediates immune evasion. PLoS Pathog., 2011, 7(9), e1002139.
[http://dx.doi.org/10.1371/journal.ppat.1002139] [PMID: 21909255]
[18]
Boechat, N.; Carvalho, A.S.; Salomão, K.; Castro, S.L.; Araujo-Lima, C.F.; Mello, F.V.C.; Felzenszwalb, I.; Aiub, C.A.F.; Conde, T.R.; Zamith, H.P.S.; Skupin, R.; Haufe, G. Studies of genotoxicity and mutagenicity of nitroimidazoles: demystifying this critical relationship with the nitro group. Mem. Inst. Oswaldo Cruz, 2015, 110(4), 492-499.
[http://dx.doi.org/10.1590/0074-02760140248] [PMID: 26018452]
[http://dx.doi.org/10.1590/0074-02760140248] [PMID: 26018452]
[19]
Trunz, B.B. Jędrysiak, R.; Tweats, D.; Brun, R.; Kaiser, M.; Suwiński, J.; Torreele, E. 1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis. Eur. J. Med. Chem., 2011, 46(5), 1524-1535.
[http://dx.doi.org/10.1016/j.ejmech.2011.01.071] [PMID: 21353728]
[http://dx.doi.org/10.1016/j.ejmech.2011.01.071] [PMID: 21353728]
[20]
Barreiro, E.J.; Kümmerle, A.E.; Fraga, C.A.M. The methylation effect in medicinal chemistry. Chem. Rev., 2011, 111(9), 5215-5246.
[http://dx.doi.org/10.1021/cr200060g] [PMID: 21631125]
[http://dx.doi.org/10.1021/cr200060g] [PMID: 21631125]
[21]
Zheng, W.; Wang, S.Y. Antioxidant activity and phenolic compounds in selected herbs. J. Agric. Food Chem., 2001, 49(11), 5165-5170.
[http://dx.doi.org/10.1021/jf010697n] [PMID: 11714298]
[http://dx.doi.org/10.1021/jf010697n] [PMID: 11714298]
[22]
Carvalho, S.A.; da Silva, E.F.; Santa-Rita, R.M.; de Castro, S.L.; Fraga, C.A.M. Synthesis and antitrypanosomal profile of new functionalized 1,3,4-thiadiazole-2-arylhydrazone derivatives, designed as non-mutagenic megazol analogues. Bioorg. Med. Chem. Lett., 2004, 14(24), 5967-5970.
[http://dx.doi.org/10.1016/j.bmcl.2004.10.007] [PMID: 15546709]
[http://dx.doi.org/10.1016/j.bmcl.2004.10.007] [PMID: 15546709]
[23]
Figueroa-Guiñez, R.; Matos, M.J.; Vazquez-Rodriguez, S.; Santana, L.; Uriarte, E.; Borges, F.; Olea-Azar, C.; Maya, J.D. Interest of antioxidant agents in parasitic diseases. The case study of coumarins. Curr. Top. Med. Chem., 2015, 15(9), 850-856.
[http://dx.doi.org/10.2174/1568026615666150220113155] [PMID: 25697564]
[http://dx.doi.org/10.2174/1568026615666150220113155] [PMID: 25697564]
[24]
Nielsen, S.F.; Christensen, S.B.; Cruciani, G.; Kharazmi, A.; Liljefors, T. Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. J. Med. Chem., 1998, 41(24), 4819-4832.
[http://dx.doi.org/10.1021/jm980410m] [PMID: 9822551]
[http://dx.doi.org/10.1021/jm980410m] [PMID: 9822551]
[25]
del Rey, B.; Ramos, A.C.; Caballero, E.; Inchaustti, A.; Yaluff, G.; Medarde, M.; Rojas de Arias, A.; San Feliciano, A. Leishmanicidal activity of combretastatin analogues and heteroanalogues. Bioorg. Med. Chem. Lett., 1999, 9(18), 2711-2714.
[http://dx.doi.org/10.1016/S0960-894X(99)00453-9] [PMID: 10509921]
[http://dx.doi.org/10.1016/S0960-894X(99)00453-9] [PMID: 10509921]
[26]
Aldunate, J.; Traipe, L.; Spencer, P.; Morello, A.; Repetto, Y. Effects of hydroquinones on intact Trypanosoma cruzi epimastigotes. Comp. Biochem. Physiol. C. Comp. Pharmacol. Toxicol., 1992, 103(1), 97-100.
[http://dx.doi.org/10.1016/0742-8413(92)90234-X] [PMID: 1360379]
[http://dx.doi.org/10.1016/0742-8413(92)90234-X] [PMID: 1360379]
[27]
Zama, S.; Bouraiou, A.; Bouacida, S.; Roisnel, T.; Belfaitah, A. Methyl 2-(2-methyl-4-nitro-1H-imidazol-1-yl)acetate. Acta Crystallogr. Sect. E Struct. Rep. Online, 2013, 69(Pt 6), 6837-6838.
[http://dx.doi.org/10.1107/S1600536813011914] [PMID: 23795026]
[http://dx.doi.org/10.1107/S1600536813011914] [PMID: 23795026]
[28]
Kaiser, C.R. 2D NMR: Inverse detection and field gradient in structure determination of organic compounds. Quim. Nova, 2000, 23(2), 231-236.
[http://dx.doi.org/10.1590/S0100-40422000000200014]
[http://dx.doi.org/10.1590/S0100-40422000000200014]
[29]
Figueiredo, J.M.; Câmara, C.A.; Amarante, E.G.; Miranda, A.L.; Santos, F.M.; Rodrigues, C.R.; Fraga, C.A.M.; Barreiro, E.J. Design and synthesis of novel potent antinociceptive agents: methyl-imidazolyl N-acylhydrazone derivatives. Bioorg. Med. Chem., 2000, 8(9), 2243-2248.
[http://dx.doi.org/10.1016/S0968-0896(00)00152-8] [PMID: 11026537]
[http://dx.doi.org/10.1016/S0968-0896(00)00152-8] [PMID: 11026537]
[30]
Lopes, A.B.; Miguez, E.; Kümmerle, A.E.; Rumjanek, V.M.; Fraga, C.A.M.; Barreiro, E.J. Characterization of amide bond conformers for a novel heterocyclic template of N-acylhydrazone derivatives. Molecules, 2013, 18(10), 11683-11704.
[http://dx.doi.org/10.3390/molecules181011683] [PMID: 24071978]
[http://dx.doi.org/10.3390/molecules181011683] [PMID: 24071978]
[31]
Lacerda, R.B.; da Silva, L.L.; de Lima, C.K.F.; Miguez, E.; Miranda, A.L.P.; Laufer, S.A.; Barreiro, E.J.; Fraga, C.A.M. Discovery of novel orally active anti-inflammatory N-phenylpyrazolyl-N-glycinyl-hydrazone derivatives that inhibit TNF-α production. PLoS One, 2012, 7(10), e46925.
[http://dx.doi.org/10.1371/journal.pone.0046925] [PMID: 23056531]
[http://dx.doi.org/10.1371/journal.pone.0046925] [PMID: 23056531]
Article Metrics
3